A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects

Xin Wu; Xiaobo Zhang; Wanjiang Feng; Haoming Feng; Zhiyu Ding; Qiangqiang Zhao; Xisheng Li; Ning Tang; Pan Zhang; Jian Li; Jianlong Wang

doi:10.1021/acsami.1c06059

journal article·2021-06-23

A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects

Xin Wu, Xiaobo Zhang, Wanjiang Feng, Haoming Feng, Zhiyu Ding, Qiangqiang Zhao, Xisheng Li, Ning Tang, Pan Zhang, Jian Li, Jianlong Wang

ACS Applied Materials & Interfaces· Volume 13· Issue 24

Publisher page

Source abstract

Abstract

Chemotherapy is one of the main treatment methods for osteosarcoma. However, conventional chemotherapy lacks targeting properties, and its long-term and extensive use will have serious side effects on patients. For this reason, a multifunctional nanodrug system (V-RZCD) targeting osteosarcoma was developed in this study. V-RZCD consists of two parts: (1) the core (ZCD), wherein calcium ions (Ca2+) and zoledronic acid (ZA) form a metal–organic framework for loading doxorubicin (DOX), and (2) the shell (V-R), a vascular endothelial growth factor (VEGF) ligand-modified red blood cell membrane nanovesicle. By targeting the VEGF, V-RZCD can specifically bind to the VEGF receptors that are highly expressed on the surface of osteosarcoma cells. Importantly, compared with free ZA and DOX, V-RZCD not only clearly inhibits the proliferation of osteosarcoma but also significantly inhibits osteolysis induced by osteosarcoma. In summary, V-RZCD represents a new way to treat osteosarcoma.

Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Department of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Department of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

Department of Infectious Diseases, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Funding

Central South University · Natural Science Foundation of??Hunan Province · National Natural Science Foundation of China · Changsha Municipal Natural Science Foundation

References (47)

Show source-provided references

1. 10.1002/adma.20190415610.1002/adma.201904156 ↗

2. 10.3390/biomedicines601001910.3390/biomedicines6010019 ↗

3. 10.1016/S2352-3026(20)30031-410.1016/S2352-3026(20)30031-4 ↗

4. 10.1016/j.nano.2015.11.01210.1016/j.nano.2015.11.012 ↗

5. 10.1021/acsami.7b0093610.1021/acsami.7b00936 ↗

6. 10.1021/acsami.0c1297110.1021/acsami.0c12971 ↗

7. 10.1021/acsami.5b0460710.1021/acsami.5b04607 ↗

8. 10.1021/acsami.9b1774710.1021/acsami.9b17747 ↗

9. 10.1021/acsami.7b1310010.1021/acsami.7b13100 ↗

10. 10.1002/smll.20160063510.1002/smll.201600635 ↗

11. 10.3390/cancers1112185510.3390/cancers11121855 ↗

12. 10.1016/j.bone.2020.11552310.1016/j.bone.2020.115523 ↗

13. 10.3390/pharmaceutics1004018010.3390/pharmaceutics10040180 ↗

14. 10.1002/jbmr.218210.1002/jbmr.2182 ↗

15. 10.2174/157339981166615061514540910.2174/1573399811666150615145409 ↗

16. 10.1242/dmm.03557610.1242/dmm.035576 ↗

17. 10.1080/14656566.2019.157475410.1080/14656566.2019.1574754 ↗

18. 10.1158/1078-0432.CCR-09-177910.1158/1078-0432.CCR-09-1779 ↗

19. 10.1093/annonc/mdv61710.1093/annonc/mdv617 ↗

20. 10.1002/asia.20180014910.1002/asia.201800149 ↗

21. 10.1259/bjr.2017089310.1259/bjr.20170893 ↗

22. 10.1021/acsami.7b1453810.1021/acsami.7b14538 ↗

23. 10.1021/acsami.7b0843310.1021/acsami.7b08433 ↗

24. 10.1021/acsnano.7b0772010.1021/acsnano.7b07720 ↗

25. 10.1039/C6BM00072J10.1039/C6BM00072J ↗

26. 10.1021/nl500618u10.1021/nl500618u ↗

27. 10.1021/acs.nanolett.8b0343910.1021/acs.nanolett.8b03439 ↗

28. 10.1002/adma.20180223310.1002/adma.201802233 ↗

29. 10.1002/smll.20160062410.1002/smll.201600624 ↗

30. 10.1021/acs.bioconjchem.6b0056910.1021/acs.bioconjchem.6b00569 ↗

31. 10.1021/acsami.0c0576310.1021/acsami.0c05763 ↗

32. 10.1038/s41413-018-0019-610.1038/s41413-018-0019-6 ↗

33. 10.1002/path.214010.1002/path.2140 ↗

34. 10.1038/s41418-020-0590-410.1038/s41418-020-0590-4 ↗

35. 10.3390/cells904097610.3390/cells9040976 ↗

36. 10.1038/s41467-020-14870-410.1038/s41467-020-14870-4 ↗

37. 10.1016/j.semcancer.2019.11.00310.1016/j.semcancer.2019.11.003 ↗

38. 10.1016/j.jtho.2020.01.00510.1016/j.jtho.2020.01.005 ↗

39. 10.1016/j.pharmthera.2020.10761110.1016/j.pharmthera.2020.107611 ↗

40. 10.3389/fbioe.2020.0037110.3389/fbioe.2020.00371 ↗

41. 10.1002/adma.20170675910.1002/adma.201706759 ↗

42. 10.1186/s13018-019-1301-z10.1186/s13018-019-1301-z ↗

43. 10.1182/blood-2018-02-79135010.1182/blood-2018-02-791350 ↗

44. 10.1111/febs.1418610.1111/febs.14186 ↗

45. 10.1016/j.intimp.2020.10638810.1016/j.intimp.2020.106388 ↗

46. 10.1021/acsami.9b1828210.1021/acsami.9b18282 ↗

47. Biteau K. · Am. J. Cancer Res. · 2016 · 6 · 677